Multiple Myeloma

Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.

Closing out their program on relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, consider optimal treatment strategies in the current landscape and look toward future directions in care.

Experts in the multiple myeloma space discuss recent developments and how to implement new practices in real-world settings.

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Following their review of data from MajesTEC-1, panelists consider how they manage patients with cytokine release syndrome in the real-world setting.

Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).

In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.

Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Key points from a discussion of the role of bispecific antibodies in the treatment of multiple myeloma.

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.

Key points from a discussion of the clinical data behind both BCMA- and non–BCMA-targeting bispecifics in multiple myeloma.

A Q&A session with the expert panel.

The expert panel discusses CAR T-cell therapy options and treatment considerations for patients with multiple myeloma.

Al-Ola Abdallah, MD, presents the case of a patient with multiple myeloma treated with CAR T-cell therapy and teclistamab.

Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.

Key opinion leaders Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, reflect on the use of tocilizumab in patients experiencing cytokine release syndrome on MajesTEC-1.

Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.